Page 2 - Efficacy Study News Today

Zygel continued to be well-tolerated with long-term administration and maintained clinically meaningful improvements in children and adolescents with Fragile X syndrome Zygel achieved statistically... | April 13, 2023

Zygel continued to be well-tolerated with long-term administration and maintained clinically meaningful improvements in children and adolescents with Fragile X syndrome Zygel achieved statistically... | April 12, 2023

12.04.2023 - Zygel continued to be well-tolerated with long-term administration and maintained clinically meaningful improvements in children and adolescents with Fragile X syndrome Zygel achieved statistically significant and clinically meaningful improvements ... Seite 1

DEVON, Pa., April 05, 2023 -- Zynerba Pharmaceuticals, Inc. , the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today... | April 5, 2023

28.02.2023 - Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND artificial intelligence and data mining platform to develop cell therapies with a focus on ... Seite 1

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

Scott Adams is the creator of the famous cartoon strip, Dilbert. It is a strip whose brilliance derives from close observation and understanding of human behavior. Some time ago, Scott turned those skills to commenting insightfully and with...

Find out the best nootropic stacks and brain supplements of 2023 based on user reviews and other forms of user engagement.

Four oral presentations presented at ASH highlight data evaluating investigational epcoritamab for the treatment of relapsed/refractory (R/R) foll...

/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced data from multiple clinical trials evaluating epcoritamab (DuoBody®-CD3xCD20), an investigational...